Literature DB >> 8264238

Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines.

M Resnicoff1, D Ambrose, D Coppola, R Rubin.   

Abstract

BACKGROUND: IGF-1 regulates the growth of diverse mammalian cell types including several human carcinoma cell lines. The IGF-1 receptor is a glycosylated heterodimer which, upon binding with IGF-1, undergoes tyrosine autophosphorylation. The autophosphorylation of the beta-receptor subunit is a strict requirement for its mitogenic properties. EXPERIMENTAL
DESIGN: In this study, we have assessed the role of the IGF-1 receptor in the proliferation of ovarian carcinoma cell lines in culture. Effects of anti-sense and sense oligodeoxynucleotides to IGF-1 receptor RNA were tested.
RESULTS: The human ovarian carcinoma cell lines OVCAR-3 and CaOV-3 both grew autonomously in serum-free medium, and their growth was further stimulated by the addition of IGF-1. Incubation of cells with anti-sense oligodeoxynucleotides corresponding to the IGF-1 receptor RNA markedly inhibited cell proliferation both in serum-free medium and in the presence of IGF-1. The inhibition of cell growth by the oligodeoxynucleotides corresponded to a reduction in the amount of detectable phosphorylated IGF-1 receptor.
CONCLUSIONS: The findings indicate that IGF-1 and its specific receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264238

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.

Authors:  P C Brooks; R L Klemke; S Schon; J M Lewis; M A Schwartz; D A Cheresh
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

4.  Anthropometric characteristics and ovarian cancer risk and survival.

Authors:  Albina N Minlikeeva; Kirsten B Moysich; Paul C Mayor; John L Etter; Rikki A Cannioto; Roberta B Ness; Kristen Starbuck; Robert P Edwards; Brahm H Segal; Sashikant Lele; Kunle Odunsi; Brenda Diergaarde; Francesmary Modugno
Journal:  Cancer Causes Control       Date:  2018-01-11       Impact factor: 2.506

5.  Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer.

Authors:  Faruk Tas; Senem Karabulut; Murat Serilmez; Rumeysa Ciftci; Derya Duranyildiz
Journal:  Tumour Biol       Date:  2013-11-20

6.  Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.

Authors:  C L Chernicky; H Tan; L Yi; J R Loret de Mola; J Ilan
Journal:  Mol Pathol       Date:  2002-04

7.  Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of insulin-like growth factor 1 receptor.

Authors:  K Akhilender Naidu; Richard C Karl; Kamatham A Naidu; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

8.  Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States).

Authors:  A I Adler; N S Weiss; M L Kamb; J L Lyon
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

9.  Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.

Authors:  Kathryn L Terry; Shelley S Tworoger; Margaret A Gates; Daniel W Cramer; Susan E Hankinson
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

Review 10.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.